A Phase II study of TNX-102 for the treatment of agitation in Alzheimer's disease

Trial Profile

A Phase II study of TNX-102 for the treatment of agitation in Alzheimer's disease

Planning
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2018 According to a Tonix Pharmaceuticals media release, a Phase II IND application was submitted in March 2018.
    • 15 Dec 2017 New trial record
    • 12 Dec 2017 According to a Tonix Pharmaceuticals media release, company had a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposed development of TNX-102. Company plans to submit the IND for agitation in Alzheimer's disease in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top